伊库利珠单抗
血栓性微血管病
补体系统
非典型溶血尿毒综合征
医学
免疫学
内皮
抗体
补语(音乐)
替代补体途径
补体成分5
单克隆抗体
内皮干细胞
补体膜攻击复合物
加药
单克隆
内科学
内皮细胞活化
药理学
CD59型
经典补体途径
血管疾病
抗体反应
同种抗体
作者
Sara Gastoldi,Elena Bresin,Andrea Pasini,Beatrice Nardini,Osmy Paci Della Costanza,Raffaela Sciri,Caterina Mele,Ariela Benigni,Giuseppe Remuzzi,Marina Noris,Sistiana Aiello
出处
期刊:
[Karger Publishers]
日期:2026-07-21
卷期号:: 1-10
摘要
INTRODUCTION: Atypical haemolytic uraemic syndrome (aHUS) is a rare and severe form of thrombotic microangiopathy caused by dysregulation of the alternative complement pathway, leading to sustained complement activation at the endothelial level and microvascular thrombosis, predominantly affecting the kidney. Anti-C5 therapy with eculizumab has markedly improved patient outcomes, with ex vivo studies showing suppression of endothelial C5b-9 deposition by sera from treated patients, in contrast to the marked C5b-9 formation induced by acute-phase sera. Ravulizumab, a long-acting anti-C5 antibody derived from eculizumab, has recently been approved for aHUS, offering extended dosing intervals and maintaining (in patients switched from eculizumab) or inducing (in de novo treated patients) disease remission. Its ability to inhibit terminal complement activation at the endothelial level has not yet been evaluated. METHODS: In this retrospective study, six patients with primary aHUS were assessed, including 4 switched from eculizumab and 2 treated de novo with ravulizumab. Serum-induced C5b-9 formation on human microvascular endothelial cells (HMEC-1) was measured ex vivo at multiple time points during treatment. RESULTS: C5b-9 formation was in normal range on HMEC-1 exposed to sera collected from all aHUS patients treated with ravulizumab, regardless of prior eculizumab exposure, and all patients remained in or achieved clinical remission. CONCLUSION: These findings provide mechanistic evidence supporting ravulizumab as an effective inhibitor of terminal complement activation and highlight ex vivo C5b-9 assessment as a potential tool for monitoring treatment efficacy in aHUS.
科研通智能强力驱动
Strongly Powered by AbleSci AI